Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity

Cellular & Molecular Immunology volume 16, pages 706–717 (2019)Cite this article

Immune-mediated, drug-induced hepatitis is a rare complication of halogenated volatile anesthetic administration. IL-4-regulated Th2-polarized reactions initiate this type and other types of hepatitis, while the mechanisms that regulate the severity remain elusive. IL-33 is an innate, IL-4-inducing, Th2-polarizing cytokine that has been detected in patients with liver failure and has been associated with upregulated ST2+Foxp3+CD4+CD25+ T cells; however, roles for IL-33 in drug-induced hepatitis are unclear. We investigated IL-33 in an anesthetic, immune-mediated hepatitis modeled in BALB/c, IL-33−/− and ST2−/− mice, as well as in patients with anesthetic hepatitis. The hepatic IL-33 and ST2 levels were elevated in BALB/c mice (p < 0.05) with hepatitis, and anti-IL-33 diminished hepatitis (p < 0.05) without reducing IL-33 levels. The complete absence of IL-33 reduced IL-10 (p < 0.05) and ST2+Foxp3+CD4+CD25+ T cells (p < 0.05), as well as reduced the overall survival (p < 0.05), suggesting suppressive roles for IL-33 in anesthetic, immune-mediated hepatitis. All of the mice demonstrated similar levels of CD4+ T-cell proliferation following direct T-cell receptor stimulation, but we detected splenic IL-33 and ST2-negative Foxp3+CD4+CD25+ T cells in ST2−/− mice that developed less hepatitis than BALB/c mice (p < 0.05), suggesting that ST2-negative Foxp3+CD4+CD25+ T cells reduced hepatitis. In patients, serum IL-33 and IPEX levels were correlated in controls (r2 = 0.5, p < 0.05), similar to the levels in mice, but not in anesthetic hepatitis patients (r2 = 0.01), who had elevated IL-33 (p < 0.001) and decreased IPEX (p < 0.01). Our results suggest that, in anesthetic, immune-mediated hepatitis, IL-33 does not regulate the CD4+ T-cell proliferation that initiates hepatitis, but IL-33, likely independent of ST2, reduces hepatitis via upregulation of Foxp3+CD4+CD25+ T cells. Further studies are needed to translate the role of IL-33 to human liver disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Bell, L. N. & Chalasani, N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis. 29, 337–347 (2009).

    Article  CAS  Google Scholar 

  2. Satoh, H. et al. Investigation of the immunological basis of halothane-induced hepatotoxicity. Adv. Exp. Med. Biol. 197, 657–673 (1986).

    Article  CAS  Google Scholar 

  3. Bourdi, M. et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem. Res. Toxicol. 9, 1159–1166 (1996).

    Article  CAS  Google Scholar 

  4. Njoku, D. B. et al. A novel model of drug hapten-induced hepatitis with increased mast cells in the BALB/c mouse. Exp. Mol. Pathol. 78, 87–100 (2005).

    Article  CAS  Google Scholar 

  5. Njoku, D. B. et al. Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury. Eur. J. Immunol. 39, 1652–1663 (2009).

    Article  CAS  Google Scholar 

  6. Cho, J. et al. Sex bias in experimental immune-mediated, drug-induced liver injury in BALB/c mice: suggested roles for Tregs, estrogen, and IL-6. PLoS ONE 8, e61186 (2013).

    Article  CAS  Google Scholar 

  7. Roth, G. A. et al. Up-regulation of interleukin 33 and soluble ST2 serum levels in liver failure. J. Surg. Res. 163, e79–e83 (2010).

    Article  CAS  Google Scholar 

  8. Wang, J., Zhao, P., Guo, H., Sun, X., Jiang, Z., Xu, L. et al. Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis C. Mediat. Inflamm. 2012, 819636 (2012).

    Google Scholar 

  9. Wang, J. et al. Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B. J. Interferon Cytokine Res. 32, 248–253 (2012).

    Article  CAS  Google Scholar 

  10. Sakai, N. et al. Interleukin-33 is hepatoprotective during liver ischemia/reperfusion in mice. Hepatology 56, 1468–1478 (2012).

    Article  CAS  Google Scholar 

  11. McHedlidze, T. et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 39, 357–371 (2013).

    Article  CAS  Google Scholar 

  12. Li, J. et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J. Clin. Invest. 124, 3241–3251 (2014).

    Article  CAS  Google Scholar 

  13. Milovanovic, M. et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol. Res. 52, 89–99 (2012).

    Article  CAS  Google Scholar 

  14. Arshad, M. I. et al. TRAIL but not FasL and TNFalpha, regulates IL-33 expression in murine hepatocytes during acute hepatitis. Hepatology 56, 2353–2362 (2012).

    Article  CAS  Google Scholar 

  15. Volarevic, V. et al. Protective role of IL-33/ST2 axis in Con A-induced hepatitis. J. Hepatol. 56, 26–33 (2012).

    Article  CAS  Google Scholar 

  16. Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564–568 (2014).

    Article  CAS  Google Scholar 

  17. Matta, B. M. et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J. Immunol. 193, 4010–4020 (2014).

    Article  CAS  Google Scholar 

  18. Noel, G. et al. Ablation of interaction between IL-33 and ST2+ regulatory T cells increases immune cell-mediated hepatitis and activated NK cell liver infiltration. Am. J. Physiol. Gastrointest. Liver Physiol. 311, G313–G323 (2016).

    Article  Google Scholar 

  19. Siede, J. et al. IL-33 receptor-expressing regulatory T cells are highly activated, Th2 biased and suppress CD4 T cell proliferation through IL-10 and TGFbeta release. PLoS ONE 11, e0161507 (2016).

    Article  Google Scholar 

  20. Ryba-Stanislawowska, M., Werner, P., Skrzypkowska, M., Brandt, A. & Mysliwska, J. IL-33 effect on quantitative changes of CD4+CD25highFOXP3+ regulatory T cells in children with type 1 diabetes. Mediat. Inflamm. 2016, 9429760 (2016).

    Article  Google Scholar 

  21. Kim, Y. H. et al. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 67, 183–190 (2012).

    Article  CAS  Google Scholar 

  22. Lee, H. Y. et al. Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma. Exp. Lung Res. 40, 66–76 (2014).

    Article  CAS  Google Scholar 

  23. Njoku, D. B. et al. IP-10 protects while MIP-2 promotes experimental anesthetic hapten - induced hepatitis. J. Autoimmun. 32, 52–59 (2009).

    Article  CAS  Google Scholar 

  24. Lopez, S. I. et al. Autoimmune hepatitis type 2 in a child with IPEX syndrome. J. Pediatr. Gastroenterol. Nutr. 53, 690–693 (2011).

    PubMed  Google Scholar 

  25. Invernizzi, P. et al. Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. BMC Gastroenterol. 12, 92 (2012).

    Article  CAS  Google Scholar 

  26. Kim, H. R. et al. Levels of circulating IL-33 and eosinophil cationic protein in patients with hypereosinophilia or pulmonary eosinophilia. J. Allergy Clin. Immunol. 126, 880–882 (2010).

    Article  Google Scholar 

  27. Liang, Y., Jie, Z., Hou, L., Aguilar-Valenzuela, R., Vu, D., Soong, L. et al. IL-33 induces nuocytes and modulates liver injury in viral hepatitis. J. Immunol. 190, 5666–5675 (2013).

    Article  CAS  Google Scholar 

  28. Oboki, K. et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl Acad. Sci. USA 107, 18581–18586 (2010).

    Article  CAS  Google Scholar 

  29. Louten, J. et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol. 23, 307–315 (2011).

    Article  CAS  Google Scholar 

  30. Rank, M. A. et al. IL-33-activated dendritic cells induce an atypical TH2-type response. J. Allergy Clin. Immunol. 123, 1047–1054 (2009).

    Article  CAS  Google Scholar 

  31. Saraiva, M. & O’Garra, A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10, 170–181 (2010).

    Article  CAS  Google Scholar 

  32. Sattler, S. et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J. Autoimmun. 50, 107–122 (2014).

    Article  CAS  Google Scholar 

  33. Kurth, M. J., Yokoi, T. & Gershwin, M. E. Halothane-induced hepatitis: paradigm or paradox for drug-induced liver injury. Hepatology 60, 1473–1475 (2014).

    Article  CAS  Google Scholar 

  34. Jaeschke, H., Xie, Y. & McGill, M. R. Acetaminophen-induced liver injury: from animal models to humans. J. Clin. Transl. Hepatol. 2, 153–161 (2014).

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge Dominic Thomas and Nicola Diny for their technical assistance and Nicole Muehleisen and Claire Levine for editorial assistance with this manuscript. This work was supported, in part, by the American Autoimmune Related Disease Association and Mr. and Mrs. Joseph Scoby and the Gail I Zuckerman foundations. Since, the initial submission of this manuscript, our technology transfer group informed us about a US patent involving the CYP2E1 epitope used in this publication. The information is as follows: Inventor: D.B.N., Invention Disclosure Title: Recognition of Critical CYP2E1 Epitopes, Issued Patent Title: Recognition of CYP2E1 Epitopes, US Patent application No. 13/203,402, Filed: 08/25/2014 by the Johns Hopkins University, Issued patent number: 9,339,531, Issue date: 5/17/2016.

Author information

Authors and Affiliations

  1. Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, 1800 Orleans Street, Suite 6349, Baltimore, MD, 21287, USA

    Merylin Cottagiri, Maeva Nyandjo, Matthew Stephens, Joel J. Mantilla & Dolores B. Njoku

  2. RIKEN Center for Developmental Biology, 2-2-3 Minatojima Minamimachi, Chuo-ku, Kobe, Japan, 650-0047

    Hirohisa Saito

  3. Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Melbourne, Australia

    Ian R. Mackay

  4. Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA

    Noel R. Rose

  5. Department of Pathology, Johns Hopkins University, 720 Rutland Avenue, Baltimore, MD, 21205, USA

    Dolores B. Njoku

Authors
  1. Merylin Cottagiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maeva Nyandjo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew Stephens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joel J. Mantilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hirohisa Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ian R. Mackay
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Noel R. Rose
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dolores B. Njoku
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dolores B. Njoku.

Ethics declarations

Conflict of interest

Ms. Cottagiri declares no potential conflict of interest. Ms Nyandjo declares no potential conflict of interest. Mr. Stephens declares no potential conflict of interest. Mr. Mantilla declares no potential conflict of interst. Dr. Saito declares no potential conlict of interest. Dr. Mackay delarees no potential conflict of interest. Dr. Rose declares no potential conflict of interest. Dr. Njoku owns a patent on the epitope utilized in this manuscript. There are no financial relationships or compensations associated with this patent.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cottagiri, M., Nyandjo, M., Stephens, M. et al. In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity. Cell Mol Immunol 16, 706–717 (2019). https://doi.org/10.1038/s41423-018-0087-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41423-018-0087-y

Keywords

This article is cited by

Search

Advanced search

Quick links